Cereno Scientific's Phase II clinical trial postponed due to Covid-19
Due to the global spread of the Sars-cov-2 virus Cereno Scientific announces that the company will postpone the planned Phase II clinical trial with the company’s lead compound CS1. The start of the study was previously planned for mid-year 2020. Cereno Scientific is adjusting planned activities to start by the end of the year, but is prepared for further adjustments if needed, due to the uncertainty of the further development of the pandemic.
Given the current situation, there are no possibilities to start the Phase II study in elective orthopedic surgery, as planned knee joint surgery is down prioritized in hospitals for the benefit of effective care to Covid-19 infected patients. In addition, the current restrictions to freedom of movement and travelling would further complicate a start of the study at the initially intended time. Due to the postponement, the company's need for additional financing will be deferred.
Cereno Scientific's preclinical work with CS014 and CS036 is ongoing as planned. Cereno Scientific's evaluation of epigenetic modulation for rare diseases is also not affected by the virus spread. The evaluation has moved into a more active phase since the company was granted Orphan Drug Designation for Pulmonary Arterial Hypertension by the U.S. Food and Drug Administration (FDA) on March 10.
For further information, please contact:
Daniel Brodén – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase II dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientific also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation and high blood pressure in the pulmonary circulation system. Cereno Scientific also has two preclinical HDAC inhibitors, CS014 and CS036. The company is located in AstraZeneca’s BioVenture Hub. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on March 30, 2020.